Home › NCT05933174

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

Who can join

Ages 45 and older · All sexes

Inclusion Criteria:

* Age ≥ 45 years
* Type 2 diabetes (diagnosed on or before 12/31/2021)
* Current/active prescription for one or more SU medications
* Established care (≥2 visits) with UH primary care provider (PCP) since 2021

Exclusion Criteria:

* Type 1 diabetes
* PCP provides a reason why patient participation is inappropriate (e.g., known cost barriers without any alternatives, prior discussion with patient about alternatives, etc.)
* Patient unable or unwilling to have conversation with their PCP regarding SU
* Unable to provide informed consent

About the study

Sulfonylurea medications are unsafe for older patients with diabetes. They are associated not only with hypoglycemia, but also with falls and increased cardiovascular risk. Yet they continue to be prescribed frequently. Indeed, older adults with type 2 diabetes, who are especially prone to adverse effects, are more likely to be prescribed sulfonylureas than younger patients. This is unfortunate since over the past several years, newer, safer, and more effective classes of medications (GLP-1 agonists and SGLT2-inhibitors) have emerged. The investigators acknowledge that sulfonylureas are inexpensive and that their low cost is a driver of continued use. However, the investigators believe patients and providers should have discussions about the risks of sulfonylureas and safer and more effective alternatives, to make diabetes care safer overall in ambulatory settings. Our research is designed to promote such discussions. The investigators will first identify patients taking sulfonylureas regularly. Next, using recommendations from AHRQ and the Canadian Deprescribing Network, the investigators will empower patients to discuss their medications with their providers through a simple question prompt sheet. Patients will be divided into an intervention group which receives explicit prompting questions, and a control group that receives a general brochure on diabetes medications. Health care providers will receive education about newer diabetes medications through case-based discussions and academic detailing. Finally the investigators will measure key outcomes including the proportion of patients who have discussions about sulfonylureas and alternatives, rates of discontinuation, and measures of control of diabetes and associated cardiovascular risks. The investigators will also evaluate the experiences of patients and providers qualitatively through brief, semi-structured interviews. Should our multi-faceted, patient-oriented intervention prove effective in promoting discussions of sulfonylureas and alternatives, and also discontinuation of sulfonylureas and switching to newer alternatives, the investigators will incorporate our prompting questions into routine care for patients taking sulfonylureas. Our intervention can be easily disseminated to other settings and therefore has considerable potential to improve safety among patients with type 2 diabetes nationwide.

What is being tested

• Prompt-sheet (other)
• Usual education (other)

Sponsor: University Hospitals Cleveland Medical Center · Participants: 220 · Started: Oct 1, 2023

Contact the study team

• Ian Neeland, MD · Phone: 216-844-5965
• Amanda Davies, MBA · Phone: 216-844-7635

Official record on ClinicalTrials.gov — NCT05933174

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.